Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 252-262

  Kostrzewa Nowak, Dorota ^a   Paine, Mark J I ^b   Korytowska, Anna ^a   Serwatka, Katarzyna ^a   Piotrowska, Sylwia ^a   Wolf, C Roland ^b   Tarasiuk, Jolanta ^a  

^a UNIVERSITY OF SZCZECIN   (Poland)

^b NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

HL60 human promyelocytic leukaemia; Mitoxantrone; Multidrug resistance; NADPH cytochrome P450 reductase; Reactive metabolites

Indexed keywords

MITOXANTRONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; VINCRISTINE;

ARTICLE; CELL STRAIN HL 60; CULTURE MEDIUM; DRUG ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOXANTRONE; NADP; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; SPECTROPHOTOMETRY;

EID: 33845672083     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.012     Document Type: Article

References (53)

1. Cheng C.C., and Zee-Cheng R.K.Y. In: Ellis G.P., and West G.B. (Eds). The design, synthesis and development of new class of potent antineoplastic anthraquinones. Progress in Medicinal Chemistry vol. 83 (1989), Elsevier, New York 118
2. Doughty J.C., Kane E., Cooke T.G., and McArdle C.S. Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer. Breast 11 (2002) 97-99
3. Khalaf A., Pfister C., Hellot M.F., Dunet F., Moussu J., and Grise P. Value of mitoxantrone in metastatic hormone-resistant prostate cancer. Prog. Urol. 12 (2002) 37-42
4. Bernardi D., Talamini R., Zanetti M., Simonelli C., Vaccher E., Spina M., and Tirelli U. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer-a phase II trial. Prostate Cancer Prostatic Dis. 7 (2004) 45-49
5. Hagemeister F., Cabanillas F., Coleman M., Gregory S.A., and Zinzani P.L. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 10 (2005) 150-159
6. Dahl B.G.V., Lacayo N.J., Brophy N., Dunussi-Joannopoulos K., Weinstein H.J., Chang M., et al. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J. Clin. Oncol. 18 (2000) 1867-1875
7. Tsimberidou A.M., Keating M.J., Giles F.J., Wierda W.G., Ferrajoli A., Lerner S., et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100 (2004) 2583-2591
8. Nowoselac A.V., Reddy S., and Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 18 (2004) 1561-1562
9. Diah S.K., Smitherman P.K., Aldridge J., Volk E.L., Schneider E., Townsend A.J., et al. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 61 (2001) 5461-5467
10. Nieth C., and Lage H. Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. J. Chemother. 17 (2005) 215-223
11. Lage H., Perlitz C., Abele R., Tampe R., Dietel M., Schadendorf D., et al. Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. Fed. Eur. Biochem. Soc. Lett. 503 (2001) 179-184
12. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl Cancer Inst. 92 (2000) 1295-1302
13. Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58 (2001) 931-959
14. Ejendal K.F., and Hrycyna C.A. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr. Protein Pept. Sci. 3 (2002) 503-511
15. Plasschaert S.L., van der Kolk D.M., de Bont E.S.J.M., Kamps W.A., Morisaki K., Bates S.E., et al. The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin. Cancer Res. 9 (2003) 5171-5177
16. Zaman G.J.R., Flens M.J., van Leusden M.R., de Haas M., Mülder H.S., Lankelma J., et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl Acad. Sci. USA 91 (1994) 8822-8826
17. Paul S., Breuninger L.M., Tew K.D., Shen H., and Kruh G.D. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specifity transporter. Proc. Natl Acad. Sci. USA 93 (1996) 6929-6934
18. Smith P.J., Morgan S.A., Fox M.E., and Watson J.V. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multidrug resistant small cell lung cancer cells. Biochem. Pharmacol. 40 (1990) 2069-2078
19. Boland M.P., Fitzgerald K.A., and O'Neill L.A.J. Topoisomerase II is required for mitoxantrone to signal nuclear factor kB activation in HL60 cells. J. Biol. Chem. 275 (2000) 25231-25238
20. Reszka K., Hartley J.A., Kolodziejczyk P., and Lown J.W. Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of 14C-labeled drug. Biochem. Pharmacol. 38 (1989) 4253-4260
21. Mewes K., Blanz J., Ehninger G., Gebhardt R., and Zeller K.P. Cytochrome P450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Res. 53 (1993) 5135-5142
22. Skladanowski A., and Konopa J. Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells. Br J. Cancer 82 (2000) 1300-1304
23. Parker B.S., Cullinane C., and Phillips D.R. Formation of DNA adducts by formaldehyde-activated mitoxantrone. Nucleic Acids Res. 27 (1999) 2918-2923
24. Parker B.S., Buley T., Evison B.J., Cutts S.M., Neumann G.M., Iskander M.N., et al. A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences. J. Biol. Chem. 279 (2004) 18814-18823
25. Parker B.S., Rephaeli A., Nudelman A., Phillips D.R., and Cutts S.M. Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation. Oncol. Res. 14 (2004) 279-290
26. Cummings J., Bartoszek A., and Smyth J.F. Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography. Studies with doxorubicin and NADPH cytochrome P-450 reductase. Anal. Biochem. 194 (1991) 146-155
27. Cullinane C., Cutts S.M., van Rosmalen A., and Phillips D.R. Formation of adriamycin-DNA adducts in vitro. Nucleic Acids Res. 22 (1994) 2296-2303
28. Skladanowski A., and Konopa J. Interstrand DNA crosslinking induced by anthracyclines in tumour cells. Biochem. Pharmacol. 47 (1994) 2269-2278
29. Taatjes D.J., Gaudiano G., Resing K., and Koch T.H. Redox pathaway leading to the alkylation of DNA by the anthracycline antitumor drugs adriamycin and daunomycin. J. Med. Chem. 40 (1997) 1276-1286
30. McGuinness B.F., Lipman R., Goldstein J., Nakanishi K., and Tomasz M. Reductive alkylation of DNA by mitomycin A, a mitomycin with high redox potential. Biochemistry 30 (1991) 6444-6453
31. Adams G.E., and Stratford I.J. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int. J. Radiat. Oncol., Biol., Phys. 29 (1994) 231-238
32. Bailey S.M., Lewis A.D., Patterson L.H., Fisher G.R., Knox R.J., and Workman P. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem. Pharmacol. 62 (2001) 461-468
33. Bartoszek A., and Wolf C.R. Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase. Biochem. Pharmacol. 43 (1992) 1449-1457
34. Cowen R.L., Patterson A.V., Telfer B.A., Airley R.E., Hobbs S., Phillips R.M., et al. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol. Cancer Ther. 2 (2003) 901-909
35. Patterson A.V., Barham H.M., Chinje E.C., Adams G.E., Harris A.L., and Stratford I.J. Importance of P450 reductase activity in determining sesitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J. Cancer 72 (1995) 1144-1150
36. Patterson A.V., Saunders M.P., Chinje E.C., Talbot D.C., Harris A.L., and Stratford I.J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR4233) and RSU1069. Br J. Cancer 76 (1997) 1338-1347
37. Chinje E.C., Patterson A.V., Saunders M.P., Lockyer S.D., Harris A.L., and Stratford I.J. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?. Br J. Cancer 81 (1999) 1127-1133
38. Cutts S.M., Nudelman A., Pillay V., Spencer D.M.S., Levovich I., Rephaeli A., et al. Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance. Oncol. Res. 15 (2005) 199-213
39. Kostrzewa-Nowak D., Paine M.J.I., Wolf C.R., and Tarasiuk J. The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J. Cancer 93 (2005) 89-97
40. Saunders M.P., Patterson A.V., Chinje E.C., Harris A.L., and Stratford I.J. NADPH: cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J. Cancer 82 (2000) 651-656
41. Tarasiuk J., Tkaczyk-Gobis K., Stefańska B., Dzieduszycka M., Priebe W., Martelli S., et al. The role of structural factors of anthraquinone compounds and their quinone-modified analogues in NADH dehydrogenase-catalysed oxygen radical formation. Anti-cancer Drug Des. 13 (1998) 923-939
42. Pawłowska J., Tarasiuk J., Wolf C.R., Paine M.J.I., and Borowski E. Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol. Res. 13 (2003) 245-252
43. Murdock K.C., Child R.G., Fabio P.F., Angier R.B., Wallace R.E., Durr F.E., et al. Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. J. Med. Chem. 22 (1979) 1024-1030
44. Smith G.C.M., Tew D., and Wolf C.R. Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc. Natl Acad. Sci. USA 91 (1994) 8710-8714
45. McGrath T., Latoud C., Arnold S.T., Safa A.R., Felsted R.L., and Center M.S. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem. Pharmacol. 38 (1989) 3611-3619
46. Marsh W., Sicheri D., and Center M.S. Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res. 46 (1986) 4053-4057
47. Chaudhary P.M., and Roninson L.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 85 (1993) 632-639
48. Traut T.W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140 (1994) 1-22
49. Won J.S., Im Y.B., Key L., Singh I., and Singh A.K. The involvement of glucose metabolism in the regulation of inducible nitric oxide synthase gene expression in glial cells: possible role of glucose-6-phosphate dehydrogenase and CCAAT/enhancing binding protein. J. Neurosci. 23 (2003) 7470-7478
50. Smyth M.J., Krasovskis E., Sutton V.R., and Johnstone R.W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl Acad. Sci. USA 95 (1998) 7024-7029
51. Schmalix W.A., Lang D., Schneider A., Bocker R., Greim H., and Doehmer J. Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines. Drug Metab. Dispos. 24 (1996) 1314-1319
52. Niitsu N., Kasukabe T., Yokoyama A., Okabe-Kado J., Yamamoto-Yamaguchi Y., Umeda M., and Honma Y. Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol. Pharmacol. 58 (2000) 27-36
53. Ramji S., Lee C., Inaba T., Patterson A.V., and Riddick D.S. Human NADPH-cytochrome P450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines. Cancer Res. 63 (2003) 6914-6919